

斯里兰卡医药制造项目



Sri Lanka Pharmaceutical Manufacturing Project

Project Code: 0525



联系我们: 樊笑雨 Laura Fan 微信 Wechat: 0094759260073

Contact us: 邮箱 Email: info@opportunitysrilanka.com

项目主体: Lanka Diagnostics (Pvt) Ltd

Project Owner: Lanka Diagnostics (Pvt) Ltd

项目总投资: 26 亿卢比 (1360 万美元)

Project Cost: LKR 2.6 Billion (US\$ 13.6 Million)

融资模式: 通过新股发行, 融资的目标是公司已发行股本的 75%。

Seeking Investment: 75% of the issued share capital of Lanka Diagnostics (Pvt) Ltd by way of an issue of new shares.

投资内部收益率: 28%

Investor IRR: 28%

投资回收期: 4 年 3 个月

Payback Period: 4.3 years

投资保障:

Investment Insure:

斯里兰卡政府保证回购计划, 15 年有效

The 15 year Government buy back guarantee (No more buy back guarantee will be issued by Sri Lanka government)

国有医药制造企业 SPMC 参股 10%

LDL has issued 10% golden shares to SPMC

第一个 5 年免税

'Zero' tax liability in the first five years

Potential to explore foreign markets through government of Sri Lanka owned brand

* 所有以上提到的数字均基于以下假设: 26 亿斯里兰卡卢比的投资, IRR 为 28%, 投资回收期为 4 年, 年生产能力为 14 亿片, 同时保持 EuGMP, WHO 和 ISO9001 2015 标准

All

the mentioned numbers above are based: on assumptions where an investment of US\$13.6 Million will have an IRR of 28% with a pay back period of 4 years with production capacity of 1.4 Billion tablets per year and while maintaining EuGMP, WHO and ISO9001 2015 standards.